Date | Price Target | Rating | Analyst |
---|---|---|---|
4/29/2024 | $40.00 | Outperform | Leerink Partners |
10/8/2021 | $56.00 → $69.00 | Buy | HC Wainwright & Co. |
9/9/2021 | $60.00 → $56.00 | Buy | Aegis Capital |
9/7/2021 | $22.00 | Outperform → Neutral | Wedbush |
9/7/2021 | $22.00 | Neutral → Underperform | Wedbush |
6/29/2021 | $60.00 | Buy | Aegis Capital |
8-K - XOMA Royalty Corp (0000791908) (Filer)
10-Q - XOMA Royalty Corp (0000791908) (Filer)
8-K - XOMA Corp (0000791908) (Filer)
Earned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA's balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well as two Phase 3 assets Launched XOMA's first stock repurchase program for up to $50 million EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royal
BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.
EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board. Mr. Hughes has served as XOMA's Executive Chairman and Interim Chief Executive Officer since January 1, 2023. "The rest of the Board and I have been impressed with Owen's leadership over the past year and his vision to establish XOMA as the premiere biotech royalty aggregator. I am looking forward to working closely with Owen and the team to further accelerate the Company's growth and maximize value for all XOMA stockholders," stated
Leerink Partners initiated coverage of XOMA with a rating of Outperform and set a new price target of $40.00
HC Wainwright & Co. reiterated coverage of XOMA with a rating of Buy and set a new price target of $69.00 from $56.00 previously
Aegis Capital reiterated coverage of XOMA with a rating of Buy and set a new price target of $56.00 from $60.00 previously
Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the acquisition of economic interests in XACIATO™ (clindamycin phosphate) vaginal gel 2%, and two novel Phase 3 assets, from Daré Bioscience Completed the acquisition of Kinnate Pharmaceuticals, adding several potential royalty streams, as well as more than $9.5 million in non-dilutive capital EMERYVILLE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, reported its second quarter 2024 financial results and highlighted rece
EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about July 15, 2024, to respec
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals' recent sale of its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. "OJEMDA™ offers patients six months of age and older who have relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG) the only approved therapy studied in and approved specifically for pLGG driven by BRAF fusions," stated Owen Hughes, Chief Executive Officer of XOMA. "With this milestone in hand, we have more than recouped
SC 13G/A - XOMA Corp (0000791908) (Subject)
SC 13D/A - XOMA Corp (0000791908) (Subject)
SC 13G/A - XOMA Corp (0000791908) (Subject)
The FDA will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee (GeMDAC) on August 2 to review the marketing application for Zevra Therapeutics Inc.’s (NASDAQ:ZVRA) arimoclomol for Niemann-Pick disease type C (NPC). The application for arimoclomol has been assigned a Prescription Drug User Fee Act (PDUFA) action date of September 21, which was extended from June 21. Previously known as KemPharm, Zevra Therapeutics acquired arimoclomol from Orphazyme for $12.8 million. In 2021, the FDA issued a complete response letter to arimoclomol as a treatment option for Niemann-Pick disease type C. The CRL asked for additional qualitative and quantitati
In the preceding three months, 5 analysts have released ratings for XOMA (NASDAQ:XOMA), presenting a wide array of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $67.2, with a high estimate of $74.00 and a low estimate of $40.00. This current average represents a 9.19% decr
HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.
EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following September 2024 investor conferences: H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, in New York, NY. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will present a corporate overview on Monday, September 9, 2024, at 9:00 AM ET. The presentation can be accessed at https://bit.ly/4coqH9K.2024 Cantor Global Healthcare Conference, which is being held September 17-19, 2024, in New York, NY. Mr. Hughes and Mr. S
Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the acquisition of economic interests in XACIATO™ (clindamycin phosphate) vaginal gel 2%, and two novel Phase 3 assets, from Daré Bioscience Completed the acquisition of Kinnate Pharmaceuticals, adding several potential royalty streams, as well as more than $9.5 million in non-dilutive capital EMERYVILLE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, reported its second quarter 2024 financial results and highlighted rece
EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about July 15, 2024, to respec
4 - XOMA Corp (0000791908) (Issuer)
4 - XOMA Corp (0000791908) (Issuer)
4 - XOMA Corp (0000791908) (Issuer)
4 - XOMA Corp (0000791908) (Issuer)
4 - XOMA Corp (0000791908) (Issuer)
4 - XOMA Corp (0000791908) (Issuer)